What is Sino Biopharmaceutical Ltd ADR?
Sino Biopharmaceutical Limited, an investment holding company, operates as a research and development pharmaceutical conglomerate in the People's Republic of China.
SBHMY · Verdict
Moderate reward · low risk
SBHMY stands out on cash flow and balance sheet, but watch the growth signal.
Based on 88% data coverage
SBHMY · Verdict
18% free-cash-flow margin
Interest covered 17.5×
12% net margin · 15% ROE
Rev +2.4% CAGR · earnings -37.9%
Model-based scoring. For information only — not financial advice.
Sino Biopharmaceutical Limited, an investment holding company, operates as a research and development pharmaceutical conglomerate in the People's Republic of China. It operates through three segments: Modernised Chinese Medicines and Chemical Medicines, Investment, and Others. The company is listed on the PINK in USA, operating in the Healthcare sector, with a market capitalisation of 20.10B, and a P/E ratio of 25.2x.
The scoring profile indicates limited reward potential at this time, with profitability and valuation offering the most support. Risk indicators are low, suggesting a relatively contained downside profile.
For informational purposes only. Not financial advice.